DR. YI HIU LIU, M.D.
Medical Practice in San Diego, CA
License number
California A75175
Category
Medical Practice
Type
Pediatrics
Address
Address
7910 Frost St. SUITE 360, San Diego, CA 92123
Phone
(858) 246-0053
(858) 496-9257 (Fax)
(858) 636-4300
(858) 636-4319 (Fax)
(858) 496-9257 (Fax)
(858) 636-4300
(858) 636-4319 (Fax)
Professional information
Chief Scientific Officer, Co-Founder At Wellspring Biosciences
Position:
Chief Scientific Officer at Wellspring Biosciences
Location:
Greater San Diego Area
Industry:
Biotechnology
Work:
Wellspring Biosciences
- San Diego since May 2012
-
Chief Scientific Officer
Intellikine (acquired by Takeda Pharmaceuticals in January 2012)
- San Diego Aug 2007 - May 2012
-
Vice President of Drug Discovery and Co-Founder
The Genomics Institute of the Novartis Research Foundation
- San Diego Aug 2002 - Jan 2007
-
Group Leader of Drug Design
SGX Pharmaceuticals
- San Diego Jul 2001 - Jun 2002
-
Senior Scientist
CuraGen Corporation
- New Haven May 1999 - Jun 2001
-
Senior Scientist
Education:
Princeton University 1994 - 1999
Ph.D., Biochemistry Beijing University 1990 - 1993
M.S., Quantum Chemistry Tsinghua University 1985 - 1990
B.E., Chemical Engineering
Ph.D., Biochemistry Beijing University 1990 - 1993
M.S., Quantum Chemistry Tsinghua University 1985 - 1990
B.E., Chemical Engineering
Dr. Yi Hui Liu, San Diego CA - MD (Doctor of Medicine)
Specialties:
Developmental-Behavioral Pediatrics
Address:
San Diego Office
200 W Arbor Dr, San Diego 92103
(858) 657-7000 (Phone), (619) 543-3183 (Fax)
200 W Arbor Dr, San Diego 92103
(858) 657-7000 (Phone), (619) 543-3183 (Fax)
Certifications:
Developmental & Behavioral Pediatrics, 2009, Pediatrics, 2009
Awards:
Healthgrades Honor Roll
Languages:
English, Chinese, Mandarin
Hospitals:
San Diego Office
200 W Arbor Dr, San Diego 92103
UCSD Medical Center - Hillcrest
200 West Arbor Dr, San Diego 92103
200 W Arbor Dr, San Diego 92103
UCSD Medical Center - Hillcrest
200 West Arbor Dr, San Diego 92103
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University
Mtor Modulators And Uses Thereof
US Patent:
2011022, Sep 15, 2011
Filed:
Jul 8, 2009
Appl. No.:
13/003562
Inventors:
Kevan M. Shokat - San Francisco CA, US
David Fruman - Irvine CA, US
Pingda Ren - San Diego CA, US
Troy Edward Wilson - San Marino CA, US
Liansheng Li - San Diego CA, US
Andrew Hsieh - San Francisco CA, US
Morris Feldman - San Francisco CA, US
Beth Apsel - San Francisco CA, US
Yi Liu - San Diego CA, US
Christian Rommel - La Jolla CA, US
Katrina Chan - San Diego CA, US
Davide Ruggero - San Francisco CA, US
David Pearce - San Francisco CA, US
Matthew Janes - Altadena CA, US
David Fruman - Irvine CA, US
Pingda Ren - San Diego CA, US
Troy Edward Wilson - San Marino CA, US
Liansheng Li - San Diego CA, US
Andrew Hsieh - San Francisco CA, US
Morris Feldman - San Francisco CA, US
Beth Apsel - San Francisco CA, US
Yi Liu - San Diego CA, US
Christian Rommel - La Jolla CA, US
Katrina Chan - San Diego CA, US
Davide Ruggero - San Francisco CA, US
David Pearce - San Francisco CA, US
Matthew Janes - Altadena CA, US
Assignee:
The Regents of the University of California, a California corporation - Oakland CA
Intellikine, Inc. - La Jolla CA
Intellikine, Inc. - La Jolla CA
International Classification:
A61K 31/506, C12N 5/09, C12N 9/99, A61K 31/519, A61K 31/436, A61P 35/00, A61P 13/12, A61P 9/12, A61P 9/04, A61P 1/16
US Classification:
51425218, 435375, 435184, 5142621, 514291
Abstract:
The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.
Compounds And Compositions As Itpkb Inhibitors
US Patent:
2012020, Aug 9, 2012
Filed:
Apr 12, 2012
Appl. No.:
13/445644
Inventors:
Badry Bursulaya - San Diego CA, US
Dai Cheng - San Diego CA, US
Jiqing Jiang - San Diego CA, US
Donald S. Karanewsky - Escondido CA, US
Yi Liu - San Diego CA, US
Shifeng Pan - San Diego CA, US
Yongqin Wan - Irvine CA, US
Xia Wang - San Diego CA, US
Yun Feng Xie - San Diego CA, US
Yang Yang - San Diego CA, US
Dai Cheng - San Diego CA, US
Jiqing Jiang - San Diego CA, US
Donald S. Karanewsky - Escondido CA, US
Yi Liu - San Diego CA, US
Shifeng Pan - San Diego CA, US
Yongqin Wan - Irvine CA, US
Xia Wang - San Diego CA, US
Yun Feng Xie - San Diego CA, US
Yang Yang - San Diego CA, US
Assignee:
IRM LLC - Hamilton
International Classification:
A61K 31/536, A61K 31/551, A61K 31/496, A61K 31/4985, C07D 487/08, A61K 31/538, C07D 401/14, A61K 31/517, A61P 37/06, A61P 29/00, A61P 19/02, A61P 17/06, A61P 7/06, A61P 35/00, C07D 413/14
US Classification:
51421016, 540575, 514218, 544 92, 5142305, 544364, 5142531, 544 94, 544105, 544368, 51425402, 544363, 51425305, 544284, 51425217, 544 70
Abstract:
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
Compounds And Compositions As Protein Kinase Inhibitors
US Patent:
7423038, Sep 9, 2008
Filed:
Jun 23, 2005
Appl. No.:
11/570661
Inventors:
Pingda Ren - San Diego CA, US
Xia Wang - San Diego CA, US
Nathanael Schiander Gray - Boston MA, US
Yi Liu - San Diego CA, US
Taebo Sim - Chestnuthill MA, US
Xia Wang - San Diego CA, US
Nathanael Schiander Gray - Boston MA, US
Yi Liu - San Diego CA, US
Taebo Sim - Chestnuthill MA, US
Assignee:
IRM LLC (a Delaware Limited Liability Corporation) - Hamilton
International Classification:
A61K 31/5355, C07D 413/10, C07D 475/00, A61P 35/00
US Classification:
5142342, 514249, 544118, 544258
Abstract:
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders than involve abnormal activation of the Abl, Bcr-abl, Bmx, c-RAF, CSK, Fes, FGFR3, Flt3, GSK3β, IR, JNK1α 1, JNK2α 2, Lck, MKK4, MKK6, p70S6K, PDGFRα, Rsk1, SAPK2α, SAPK2β, Syk and Trkβ kinases.
Compounds And Compositions As Itpkb Inhibitors
US Patent:
8178526, May 15, 2012
Filed:
Jun 12, 2008
Appl. No.:
12/664651
Inventors:
Badry Bursulaya - San Diego CA, US
Dai Cheng - San Diego CA, US
Jiqing Jiang - San Diego CA, US
Donald S. Karanewsky - Escondido CA, US
Yi Liu - San Diego CA, US
Shifeng Pan - San Diego CA, US
Yongqin Wan - Irvine CA, US
Xia Wang - San Diego CA, US
Yun Feng Xie - San Diego CA, US
Yang Yang - San Diego CA, US
Dai Cheng - San Diego CA, US
Jiqing Jiang - San Diego CA, US
Donald S. Karanewsky - Escondido CA, US
Yi Liu - San Diego CA, US
Shifeng Pan - San Diego CA, US
Yongqin Wan - Irvine CA, US
Xia Wang - San Diego CA, US
Yun Feng Xie - San Diego CA, US
Yang Yang - San Diego CA, US
Assignee:
IRM LLC - Hamilton
International Classification:
C07D 413/02, C07D 413/14, A61K 31/536, A61K 31/551
US Classification:
5142305, 51425213, 51425305, 51425306, 544 92, 544105, 544359, 544363
Abstract:
The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
Benzoxazole Kinase Inhibitors And Methods Of Use
US Patent:
8450329, May 28, 2013
Filed:
Sep 17, 2009
Appl. No.:
12/586309
Inventors:
Pingda Ren - San Diego CA, US
Yi Liu - San Diego CA, US
Troy Edward Wilson - San Marino CA, US
Liansheng Li - San Diego CA, US
Katrina Chan - San Diego CA, US
Yi Liu - San Diego CA, US
Troy Edward Wilson - San Marino CA, US
Liansheng Li - San Diego CA, US
Katrina Chan - San Diego CA, US
Assignee:
Intellikine LLC - La Jolla CA
International Classification:
C07D 487/04, A61K 31/519, A61P 35/00, A61P 29/00, A61P 9/00
US Classification:
5142621, 544262, 544280, 5142651
Abstract:
The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. For example, the invention provides compounds of Formula:Also provided in the present invention are methods of using such compounds or compositions, and methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications such as treatment of cancer.
Noncovalent Functionalization Of Nanotubes
US Patent:
2007011, May 24, 2007
Filed:
Jan 16, 2007
Appl. No.:
11/653364
Inventors:
J. Stoddart - Los Angeles CA, US
Alexander Star - Pittsburgh PA, US
Yi Liu - San Diego CA, US
Ludek Ridvan - Praha, CZ
Alexander Star - Pittsburgh PA, US
Yi Liu - San Diego CA, US
Ludek Ridvan - Praha, CZ
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C08G 75/32
US Classification:
528377000
Abstract:
Nanotubes are treated with poly{(5-alkoxy-m-phenylenevinylene)-co-[(2,5-dioctyloxy-p-phenylene)vinylene]} (PAmPV) polymers and derivatives thereof to provide noncovalent functionalization of the nanotubes which increases solubility and enhances other properties.
Compounds And Compositions As Protein Kinase Inhibitors
US Patent:
2013001, Jan 10, 2013
Filed:
Sep 14, 2012
Appl. No.:
13/617881
Inventors:
Qiang DING - Beijing, CN
Nathanael Schiander GRAY - Boston MA, US
Bing LI - Westborough MA, US
Yi LIU - San Diego CA, US
Taebo SIM - Seoul, KR
Tetsuo UNO - San Diego CA, US
Guobao ZHANG - San Diego CA, US
Carole Pissot Soldermann - Village Neuf, FR
Werner BREITENSTEIN - Basel, CH
Guido BOLD - Gipf-Oberfrick, CH
Giorgio CARAVATTI - Bottmingen, CH
Pascal FURET - Thann, FR
Vito GUAGNANO - Basel, CH
Marc LANG - Mulhouse, FR
Paul W. MANLEY - Arlesheim, CH
Joseph SCHOEPFER - Riehen, CH
Carsten SPANKA - Lorrach, DE
Nathanael Schiander GRAY - Boston MA, US
Bing LI - Westborough MA, US
Yi LIU - San Diego CA, US
Taebo SIM - Seoul, KR
Tetsuo UNO - San Diego CA, US
Guobao ZHANG - San Diego CA, US
Carole Pissot Soldermann - Village Neuf, FR
Werner BREITENSTEIN - Basel, CH
Guido BOLD - Gipf-Oberfrick, CH
Giorgio CARAVATTI - Bottmingen, CH
Pascal FURET - Thann, FR
Vito GUAGNANO - Basel, CH
Marc LANG - Mulhouse, FR
Paul W. MANLEY - Arlesheim, CH
Joseph SCHOEPFER - Riehen, CH
Carsten SPANKA - Lorrach, DE
International Classification:
C07D 403/12, C07C 265/12, C07D 413/12, C07D 405/12, C07D 409/14, C07D 401/12, C07D 401/14, C07C 217/84, C07D 239/48
US Classification:
544122, 544295, 564442, 560358, 544322
Abstract:
The invention relates to compounds of formula (I)wherein the substituents X, R, R, Rand Rhave the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
Heterocyclic Compounds And Uses Thereof
US Patent:
2013026, Oct 3, 2013
Filed:
May 24, 2011
Appl. No.:
13/699611
Inventors:
Pingda Ren - San Diego CA, US
Yi Liu - San Diego CA, US
Liansheng Li - San Diego CA, US
Katrina Chan - Fremont CA, US
Troy Edward Wilson - San Marino CA, US
Simon Fraser Campbell - Kent, GB
Yi Liu - San Diego CA, US
Liansheng Li - San Diego CA, US
Katrina Chan - Fremont CA, US
Troy Edward Wilson - San Marino CA, US
Simon Fraser Campbell - Kent, GB
International Classification:
C07D 471/04
US Classification:
51421021, 544362, 435184, 51425304, 544127, 5142345
Abstract:
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.